

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Sands Capital Ventures Discovery Fund III, L.P.</u> (Last) (First) (Middle) 1000 WILSON BLVD., SUITE 3000 (Street) ARLINGTON VA 22209 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 06/30/2021	3. Issuer Name and Ticker or Trading Symbol <u>Acumen Pharmaceuticals, Inc. [ABOS]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Series A-1 Preferred Stock	(1)	(1)	Common Stock	1,124,729	(1)	D ⁽²⁾⁽⁴⁾
Series B Preferred Stock	(1)	(1)	Common Stock	1,842,346	(1)	D ⁽³⁾⁽⁴⁾

1. Name and Address of Reporting Person*
Sands Capital Ventures Discovery Fund III, L.P.
 (Last) (First) (Middle)
 1000 WILSON BLVD., SUITE 3000
 (Street)
 ARLINGTON VA 22209
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Sands Capital Global Venture Fund II, L.P.
 (Last) (First) (Middle)
 1000 WILSON BLVD, SUITE 3000
 (Street)
 ARLINGTON VA 22209
 (City) (State) (Zip)

1. Name and Address of Reporting Person*

Sands Capital Life Sciences Pulse Fund, LLC

(Last) (First) (Middle)

1000 WILSON BLVD, SUITE 3000

(Street)

ARLINGTON VA 22209

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

SANDS FRANK M.

(Last) (First) (Middle)

1000 WILSON BLVD, SUITE 3000

(Street)

ARLINGTON VA 22209

(City)

(State)

(Zip)

Explanation of Responses:

1. Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock will automatically convert into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. The Series A-1 Preferred and the Series B Preferred Stock have no expiration date.
2. Represents Series A-1 Preferred Stock held by Sands Capital Ventures Discovery Fund III, L.P. ("Sands Discovery Fund "). Sands Capital Ventures Discovery Fund III-GP, LLC ("Sands Discovery GP") is the general partner of Sands Discovery Fund. Sands Discovery GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Frank M. Sands holds ultimate voting and investment power over these securities and may be deemed to beneficially own the securities.
3. Represents 921,173 shares of Series B Preferred Stock held by Sands Capital Global Venture Fund II, L.P. ("Sands Venture Fund") and 921,173 shares of Series B Preferred Stock held by Sands Capital Life Sciences Pulse Fund, LLC ("Sands Pulse Fund"). Sands Capital Global Venture Fund II-GP, L.P. ("Sands Venture GP L.P.") is the general partner of Sands Venture Fund. Sands Capital Global Venture Discovery Fund II-GP, LLC ("Sands Venture GP LLC") is the general partner of Sands Venture GP L.P. Sands Venture GP L.P. and Sands Venture GP LLC each disclaim beneficial ownership of such securities except to the extent of their relative pecuniary interest therein.
4. Frank M. Sands holds ultimate voting and investment power over securities held by Sands Discovery Fund, Sands Venture Fund and Sands Pulse Fund. Mr. Sands disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Remarks:

/s/ Jonathan Goodman,
General Counsel of Sands
Capital Ventures
Discovery Fund III-GP, LLC, the General Partner
of Sands Capital Ventures
Discovery Fund III, L.P. 06/30/2021

/s/ Jonathan Goodman,
General Counsel of Sands
Capital Global Venture
Discovery Fund II-GP,
LLC, the General Partner
of Sands Capital Global
Venture Fund II-GP, L.P.,
the General Partner of
Sands Capital Venture
Fund II, L.P. 06/30/2021

/s/ Jonathan Goodman,
General Counsel of Sands
Capital Life Sciences
Pulse Fund, LLC 06/30/2021

/s/ Frank M. Sands 06/30/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.